<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of osteoporosis in men</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of osteoporosis in men</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of osteoporosis in men</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel S Finkelstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine W Yu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is a leading cause of morbidity and mortality in older people. While less common in men than women, the mortality rate associated with hip fractures [<a href="#rid1">1,2</a>], as well as vertebral and other major fractures [<a href="#rid3">3</a>], is higher in men than in women; in part, this is related to older age and a greater number of comorbid conditions at the time of fracture. In addition, men are even less likely than women to be evaluated or receive antiresorptive therapy after a hip fracture (4.5 versus 49.5 percent, respectively) [<a href="#rid4">4-6</a>].</p><p>The treatment of osteoporosis in men consists of lifestyle measures, hormonal therapy (when indicated), and/or drug therapy. An overview of the approach to therapy of osteoporosis in men will be presented here. The diagnosis, evaluation, and epidemiology of osteoporosis in men are discussed separately. (See  <a class="medical medical_review" href="/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men"</a> and  <a class="medical medical_review" href="/d/html/2049.html" rel="external">"Etiology of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LIFESTYLE MEASURES</span><span class="headingEndMark"> — </span>In general, lifestyle modifications should be encouraged for all men with osteoporosis. A weight-bearing exercise regimen may be modestly beneficial, given the association of reduced physical activity with bone loss and fracture in older men and the positive effect of exercise in women with osteoporosis (see  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Exercise'</a> and  <a class="medical medical_review" href="/d/html/2049.html" rel="external">"Etiology of osteoporosis in men", section on 'Lifestyle factors'</a>). In addition, smoking and excessive alcohol intake should be avoided.</p><p>The Recommended Daily Allowance for total calcium intake (from diet and supplements) in men is 1000 mg per day for men aged 19 to 70 years and 1200 mg per day for men aged 71 years and older. The Recommended Daily Allowance for vitamin D is 600 international units (15 mcg) per day for men aged 19 to 70 years and 800 international units (20 mcg) per day for men aged 71 years and older. Older persons confined indoors and other high-risk groups may have low serum 25-hydroxyvitamin D (25[OH]D) concentrations at this intake level and may require higher intakes of vitamin D. (See  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Groups at high risk'</a>.)</p><p>In some trials, vitamin D has been shown to reduce fracture risk in adults when administered at a dose of at least 700 international units/day and when given with calcium supplements (see  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>). However, in most cases, the addition of pharmacologic therapy is necessary for the treatment of osteoporosis in men [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">MANAGEMENT OF UNDERLYING CONDITIONS</span><span class="headingEndMark"> — </span>If osteoporosis is due to another condition (eg, hypogonadism, gastrointestinal disease, hypercalciuria), the underlying cause should be treated and potential offending agents (eg, glucocorticoids, alcohol, tobacco) should be eliminated whenever possible. Many conditions may contribute to osteoporosis in men  (<a class="graphic graphic_table graphicRef60440" href="/d/graphic/60440.html" rel="external">table 1</a>). Some of the more common underlying causes are reviewed below. (See  <a class="medical medical_review" href="/d/html/2049.html" rel="external">"Etiology of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H3669196428"><span class="h2">Hypogonadism</span><span class="headingEndMark"> — </span>For hypogonadal men who have a high risk for fracture, we suggest the addition of osteoporosis pharmacotherapy to <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy. (See <a class="local">'Patient selection'</a> below and <a class="local">'Choice of therapy'</a> below.)</p><p>The impact of hypogonadism on bone mineral density (BMD) and fracture risk in men is reviewed separately, as are the diagnosis and treatment of male hypogonadism. (See  <a class="medical medical_review" href="/d/html/2049.html" rel="external">"Etiology of osteoporosis in men", section on 'Hypogonadism'</a> and  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> therapy has skeletal benefits in men with serum testosterone levels below the normal range, as illustrated by the studies described below.</p><p class="headingAnchor" id="H4"><span class="h3">Congenital hypogonadism</span><span class="headingEndMark"> — </span>Severe hypogonadism (serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in the prepubertal range) is seen in men with idiopathic hypogonadotropic hypogonadism (IHH) [<a href="#rid8">8</a>] and in some men with Klinefelter syndrome or other congenital disorders. In men with IHH, BMD is low and increases modestly with androgen replacement [<a href="#rid9">9</a>]. Androgen replacement leads to greater increases in BMD if initiated before skeletal maturity [<a href="#rid9">9,10</a>]. Nonetheless, in men with congenital forms of hypogonadism, BMD remains substantially lower than in eugonadal, healthy men despite prolonged testosterone replacement.</p><p class="headingAnchor" id="H724183090"><span class="h3">Acquired hypogonadism</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypogonadism due to an underlying disorder</strong> – Severe acquired hypogonadism is uncommon but can occur in men with pituitary tumors or testicular damage. In men with acquired hypogonadism due to an identifiable organic disorder, BMD is reduced and increases modestly with <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy (eg, 5 percent by spine dual-energy x-ray absorptiometry [DXA] and 14 percent by quantitative computed tomography [QCT] in one report) [<a href="#rid11">11</a>]. The response to testosterone administration is greatest in previously untreated men with the lowest BMD at baseline [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Functional hypogonadism</strong> – In men with functional hypogonadism (ie, age-related declines in <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a>, or "low T" syndrome), the effects of testosterone administration on fracture risk remain uncertain. Given this uncertainty, we agree with the recommendation from the Endocrine Society to add a pharmacologic agent with proven antifracture efficacy (eg, a bisphosphonate or <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a>) in testosterone-treated hypogonadal men with high risk of fracture [<a href="#rid12">12</a>]. (See <a class="local">'Patient selection'</a> below and <a class="local">'Choice of therapy'</a> below.)</p><p></p><p class="bulletIndent1">Only a few trials have examined the skeletal effects of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> in older men with low serum testosterone levels due to functional hypogonadism. Two small trials (n = 70 and n = 48) in men aged ≥60 or 65 years with testosterone levels below the reference range reported improvement in spine BMD by DXA with testosterone supplementation [<a href="#rid13">13,14</a>]. However, in another trial of 108 men, changes in BMD were similar in men treated with testosterone or placebo, probably because the mean baseline testosterone concentration (367 ng/dL [12.7 nmol/L]) was too high to demonstrate a beneficial effect on BMD [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">In the <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> Trials, men aged ≥65 years (n = 211) with baseline serum testosterone level &lt;275 ng/dL (9.5 nmol/L) were randomly assigned to treatment with testosterone or placebo. After 12 months, testosterone therapy led to a greater increase in mean lumbar spine trabecular volumetric BMD (7.5 versus 0.8 percent)  (<a class="graphic graphic_figure graphicRef117100" href="/d/graphic/117100.html" rel="external">figure 1</a>), as well as greater increases in lumbar peripheral volumetric BMD (as measured by QCT) and hip trabecular and peripheral volumetric BMD [<a href="#rid16">16</a>]. To a lesser degree, testosterone also increased areal BMD of the lumbar spine by DXA. (See  <a class="medical medical_review" href="/d/html/7457.html" rel="external">"Approach to older males with low testosterone"</a>.)</p><p></p><p class="bulletIndent1">In one physiologic study, declines in BMD due to gonadal steroid deficiency generally did not occur until <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels approached 200 ng/dL (6.9 nmol/L) or below [<a href="#rid17">17</a>]. Thus, the relatively modest increase in BMD with testosterone administration in the Testosterone Trials is perhaps not surprising given that the average baseline testosterone level was 230 ng/dL (8 nmol/L). Of note, none of the published testosterone trials has evaluated the impact of testosterone on fracture risk, although the TRAVERSE trial may provide data about this important outcome [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H20461678"><span class="h2">Glucocorticoid-induced osteoporosis</span><span class="headingEndMark"> — </span>Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher BMD values than those associated with fracture in postmenopausal osteoporosis. The increased risk of fracture has been reported with doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent as low as 2.5 to 7.5 mg daily. (See  <a class="medical medical_review" href="/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis", section on 'Epidemiology and risk factors'</a>.)</p><p>Glucocorticoid-induced bone loss should be treated aggressively, particularly in individuals at high risk for fracture (eg, prior fragility fracture, high-dose glucocorticoids, frequent falls). In other individuals, clinical risk factor and BMD assessment may help guide therapy. The prevention and treatment of glucocorticoid-induced bone loss in adults is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H3195499"><span class="h2">Androgen deprivation therapy</span><span class="headingEndMark"> — </span>Androgen deprivation therapy (bilateral orchiectomy or gonadotropin-releasing hormone [GnRH] agonist administration) reduces BMD in men with prostate cancer and increases the risk of clinical fractures. The management of osteoporosis in men treated with androgen deprivation therapy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Osteoporosis and bone fractures'</a>.)</p><p class="headingAnchor" id="H4036820224"><span class="h2">Gastrointestinal disorders</span><span class="headingEndMark"> — </span>Osteoporosis is common in patients with malabsorptive disorders (eg, celiac disease) and in those with inflammatory bowel diseases (eg, Crohn disease, ulcerative colitis). In patients with celiac disease, osteoporosis is due, in part, to secondary hyperparathyroidism related to vitamin D deficiency. In patients with severely low vitamin D levels (and particularly if the serum parathyroid hormone [PTH] is high), the need for osteoporosis therapy should be re-evaluated <strong>after</strong> vitamin D repletion. In patients with severe vitamin D deficiency, osteomalacia may be present, and BMD may increase markedly with vitamin D and calcium administration alone. (See  <a class="medical medical_review" href="/d/html/2040.html" rel="external">"Clinical manifestations, diagnosis, and treatment of osteomalacia in adults", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a>.)</p><p>Similarly, treatment of celiac disease with a gluten-free diet may be sufficient for a significant improvement in BMD. (See  <a class="medical medical_review" href="/d/html/4777.html" rel="external">"Management of celiac disease in adults", section on 'Dietary counseling'</a>.)</p><p>Patients with inflammatory bowel disease have multiple potential causes of osteoporosis, including disease-related inflammatory activity, glucocorticoid therapy, hypogonadism, and nutritional deficiencies. The treatment of osteoporosis in patients with inflammatory bowel disease is reviewed separately. (See  <a class="medical medical_review" href="/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2629508137"><span class="h2">Hypercalciuria</span><span class="headingEndMark"> — </span>BMD is frequently reduced in men with hypercalciuria. Reduced BMD is most often observed in men who have fasting hypercalciuria and PTH levels in the lower end of the normal range, suggesting that urinary calcium is increased because of excessive bone resorption rather than increased calcium absorption or a primary renal calcium leak. For these men, a low-calcium diet should be <strong>avoided</strong> as it may further exacerbate BMD losses. (See <a class="local">'Lifestyle measures'</a> above.)</p><p class="headingAnchor" id="H1554186004"><span class="h1">OSTEOPOROSIS PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H6"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Men with the highest risk of fracture are the ones most likely to benefit from osteoporosis drug therapy; therefore, patient selection should be based upon fracture risk, as determined by a combination of bone mineral density (BMD) and clinical risk factors. The following approach is largely in agreement with guidelines from the Bone Health and Osteoporosis Foundation (BHOF, previously the National Osteoporosis Foundation [NOF]) and the Endocrine Society<strong> </strong> (<a class="graphic graphic_table graphicRef52512" href="/d/graphic/52512.html" rel="external">table 2</a>) [<a href="#rid12">12,19</a>]. Additional guidelines have been published for the treatment of osteoporosis in men. Although these guidelines are useful, osteoporosis treatment should remain individualized through shared decision-making between patient and clinician. (See <a class="local">'Society guideline links'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>For men with osteoporosis (history of fragility fracture, or a T-score below -2.5 in men aged ≥50 years), we recommend osteoporosis pharmacotherapy. This recommendation is widely accepted, though largely based on the proven efficacy of pharmacologic therapy in women with osteoporosis. (See <a class="local">'Choice of therapy'</a> below and  <a class="medical medical_review" href="/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For testosterone-treated hypogonadal men who have a high risk for fracture, we suggest the addition of osteoporosis pharmacotherapy to <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy. In the absence of definitive data upon which to objectively classify fracture risk in hypogonadal men, we consider high risk to include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-dose glucocorticoids</p><p class="bulletIndent2"><span class="glyph">•</span>Frequent falls</p><p class="bulletIndent2"><span class="glyph">•</span>Recent fragility fracture, particularly with a BMD T-score ≤-2.5 at any skeletal site</p><p class="bulletIndent2"><span class="glyph">•</span>BMD T-score ≤-3.0</p><p class="bulletIndent2"><span class="glyph">•</span>BMD T-score ≤-2.5 after adequate <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy for ≥2 years (based upon clinical trial data in men showing that testosterone continues to improve BMD for at least two years [<a href="#rid13">13</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For men aged ≥50 years with T-scores between -1.0 and -2.5 who are at high risk for fracture, we suggest osteoporosis pharmacotherapy. One commonly used definition of high fracture risk is a 10-year probability of hip fracture or combined major osteoporotic fracture of ≥3.0 or ≥20 percent, respectively (using the Fracture Risk Assessment Tool [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2059" target="_blank">FRAX</a>]). However, this strategy has not been assessed in clinical trials. A reasonable alternative is to provide pharmacologic treatment to men with low bone mass (T-scores between -1.0 and -2.5) and any condition known to increase fracture risk  (<a class="graphic graphic_table graphicRef60440" href="/d/graphic/60440.html" rel="external">table 1</a>) (eg, high-dose glucocorticoid therapy, gonadotropin-releasing hormone [GnRH] agonist therapy, frequent falls, prior organ transplantation), particularly if the underlying condition cannot be adequately addressed.</p><p></p><p class="bulletIndent1">The FRAX criteria for pharmacologic intervention were chosen on the basis of a United States-specific economic analysis. Intervention thresholds have been estimated for other countries based upon assessment of absolute fracture risk and country-specific analyses and may be accessed directly from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2059" target="_blank">FRAX</a> website. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 2010 Osteoporosis Canada guidelines recommend pharmacologic therapy for men (and women) with a high 10-year absolute risk (&gt;20 percent probability for major osteoporotic fracture) and for individuals aged ≥50 years who have sustained a fragility fracture [<a href="#rid20">20</a>]. For individuals at moderate risk for fracture (10 to 20 percent), the decision to treat should be based upon the presence of additional risk factors not considered in the risk assessment system and upon individual preference.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the United Kingdom, the National Osteoporosis Guideline Group recommends an age-dependent intervention threshold for men (and women), which ranges from 7.5 to 30 percent for ages 50 to 80 years [<a href="#rid21">21</a>].</p><p></p><p>In an analysis of data from a population-based cohort of 5880 older men (mean age 73.6 years), the proportion of men identified for osteoporosis treatment varied from 2.2 to 25.3 percent, depending upon the criteria used to assess osteoporosis and the risk for fracture [<a href="#rid22">22</a>]. Use of the BMD criteria proposed by the World Health Organization (WHO; femoral neck T-score ≤-2.5 derived from female reference database) identified the fewest men for osteoporosis treatment (2.2 percent), whereas use of the FRAX intervention thresholds set by the BHOF for men with BMD T-scores between -1 and -2.5 identified the most men for treatment (25.3 percent). During the 10-year follow-up period, 177 men (3 percent) had a hip fracture. The observed 10-year fracture probabilities were highest among the men identified as having osteoporosis by the WHO BMD criteria (20.6 versus 9.5 percent using FRAX thresholds set by the BHOF). Of note, the use of a male reference database (rather than a female reference database as proposed by the WHO) to calculate T-scores leads to the identification of many more men for treatment. (See  <a class="medical medical_review" href="/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'</a> and  <a class="medical medical_review" href="/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry", section on 'Reference databases'</a>.)</p><p class="headingAnchor" id="H20048148"><span class="h2">Choice of therapy</span><span class="headingEndMark"> — </span>Males and females seem to respond comparably to available osteoporosis pharmacotherapies, so the approach to treatment is generally similar. Nonetheless, few trials have evaluated the impact of pharmacologic agents on fracture risk reduction in men [<a href="#rid23">23,24</a>]. In the absence of high-quality, head-to-head drug comparison trials to determine the relative efficacy of the individual drugs, choice of therapy should be based upon efficacy, safety, cost, convenience, and other patient-related factors. Recommendations for initial treatment may differ for men with severe osteoporosis. (See <a class="local">'Severe osteoporosis'</a> below.)</p><p class="headingAnchor" id="H4194324901"><span class="h3">Initial therapy: Bisphosphonates</span><span class="headingEndMark"> — </span>For most men who require pharmacologic therapy, we suggest oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. In a meta-analysis of trials in men with osteoporosis, bisphosphonates reduced the risk of vertebral (six trials, relative risk [RR] 0.37, 95% CI 0.25-0.54) and nonvertebral (four trials, RR 0.60, 95% CI 0.40-0.90) fracture [<a href="#rid25">25</a>].</p><p>Among the available oral bisphosphonates, we (and others) suggest weekly <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> [<a href="#rid12">12,20,26,27</a>]. In randomized trials, alendronate and risedronate improved BMD and significantly reduced the risk of vertebral fracture [<a href="#rid28">28-33</a>]. As an example, in a two-year, open-label trial of 316 men with osteoporosis who were randomly assigned to risedronate (5 mg daily) or an active comparator group (<a class="drug drug_general" data-topicid="16467" href="/d/drug information/16467.html" rel="external">alfacalcidol</a> or vitamin D), the incidence of vertebral fractures was significantly lower in the risedronate group (9.2 versus 23.6 percent) [<a href="#rid32">32</a>]. In a meta-analysis of trials evaluating individual osteoporosis drugs in men with osteoporosis, there was a significant reduction in the risk of vertebral fractures with alendronate (two trials, RR 0.33, 95% CI 0.16–0.69) and risedronate (two trials, RR 0.43, 95% CI 0.24–0.75) [<a href="#rid25">25</a>].</p><p>The dosing, adverse effects, and the prescribing instructions designed to minimize gastrointestinal side effects of oral bisphosphonates are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'General Principles'</a> and  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Risks specific to oral bisphosphonates'</a>.)</p><p>Bisphosphonates are generally not recommended for individuals with an estimated glomerular filtration rate (eGFR) below 30 to 35 mL/min/1.73 m<sup>2</sup>, although the evidence upon which this practice is based is limited. Management of osteoporosis in people with chronic kidney disease is reviewed separately. (See  <a class="medical medical_review" href="/d/html/13914.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Diagnosis and evaluation"</a> and  <a class="medical medical_review" href="/d/html/114322.html" rel="external">"Osteoporosis in patients with chronic kidney disease: Management"</a>.)</p><p class="headingAnchor" id="H4281205351"><span class="h4">Contraindications or intolerance to oral bisphosphonates</span><span class="headingEndMark"> — </span>Intravenous (IV) bisphosphonates (<a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> and <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>) are an alternative for individuals who cannot tolerate oral bisphosphonates or who find the IV dosing regimen more convenient. Zoledronic acid is the only IV bisphosphonate that has demonstrated efficacy for fracture prevention in men [<a href="#rid34">34,35</a>], and it is therefore our agent of choice.</p><p>Men who have esophageal disorders (achalasia, scleroderma involving the esophagus, esophageal strictures, varices), gastrointestinal intolerance to oral bisphosphonates, or an inability to follow the dosing requirements of oral bisphosphonates (including an inability to sit upright for 30 to 60 minutes and/or to swallow a pill) should not be treated with oral bisphosphonates. Oral bisphosphonates should also be avoided after certain types of bariatric surgery (eg, Roux-en-Y gastric bypass) due to uncertainty about medication absorption/bioavailability and theoretical risk for damage to surgical anastomoses within the gastrointestinal tract.</p><p>In the absence of direct fracture efficacy data for IV <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>, we prefer <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> based upon the following trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Health Outcomes and Reduced Incidence with <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic Acid</a> Once Yearly (HORIZON) Recurrent Fracture Trial, 2127 adults with hip fracture were randomly assigned to receive yearly zoledronic acid (5 mg) or placebo within three months of surgical repair [<a href="#rid34">34</a>]. Patients also received vitamin D, if the 25-hydroxyvitamin D [25(OH)D] concentration was &lt;15 mg/dL or unknown, and calcium. After a median follow-up of 1.9 years, new fractures occurred in 8.6 and 13.9 percent of individuals in the zoledronic acid and placebo groups, respectively, representing a relative risk (RR) reduction of 35 percent (hazard ratio [HR] 0.65, 95% CI 0.50-0.84). All-cause mortality, a secondary safety endpoint, was lower in the zoledronic acid group compared with placebo group (HR 0.72, 95% CI 0.56-0.93).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate trial, 1199 men with primary or hypogonadism-associated osteoporosis (mean T-score femoral neck -2.23, approximately 30 percent with prevalent vertebral fractures) were randomly assigned to <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> (5 mg IV) or placebo at baseline and 12 months [<a href="#rid35">35</a>]. All patients received calcium and vitamin D supplementation. After two years, there were fewer morphometric vertebral fractures in the zoledronic acid group (1.6 versus 4.9 percent in the placebo group, RR 0.33, 95% CI 0.16-0.70).</p><p></p><p>Prior to receiving IV bisphosphonates, patients should be assessed for hypocalcemia, vitamin D deficiency, and kidney impairment by measuring serum calcium, creatinine, and 25(OH)D. It is unclear what level of 25(OH)D is desirable prior to IV bisphosphonate infusion, although many experts recommend levels of at least 20 to 25 ng/mL (50 to 62 nmol/L). Additional information regarding dosing, adverse effects, and the prescribing instructions designed to minimize adverse effects is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'IV regimen'</a> and  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>.)</p><p class="headingAnchor" id="H31012406"><span class="h4">Contraindications/intolerance to any bisphosphonates</span><span class="headingEndMark"> — </span>For men who cannot tolerate oral or IV bisphosphonates, options include bone anabolic agents (eg, <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> [PTH (1-34)], <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a> [parathyroid hormone-related protein (PTHrP) (1-34)]) or <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTH/PTHrP analogs</strong> – <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">Teriparatide</a> and <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a> are generally reserved for men who have failed previous therapy (eg, continue to fracture after one year of bisphosphonate therapy) or men with severe osteoporosis (low BMD [T-score &lt;-2.5] and at least one fragility fracture, T-score of ≤-3.0 even in the absence of fractures, severe or multiple vertebral fractures). (See <a class="local">'Severe osteoporosis'</a> below and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Choice of therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Teriparatide</strong> – In the largest trial to date, 437 men with osteoporosis were randomly assigned to receive <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> (20 or 40 mcg/day by subcutaneous injection) or placebo. After 11 months of treatment, teriparatide increased spine and femoral neck BMD more than placebo (5.9 and 9 percent in the low- and high-dose groups at the spine; 1.5 and 2.9 percent in the low- and high-dose groups at the femoral neck) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Abaloparatide</strong> – In a randomized trial of <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a> or placebo in 228 men whose mean lumbar spine T-score was -2.1, approximately 35 percent of whom had prevalent vertebral fractures, abaloparatide increased BMD at the lumbar spine and total hip more than placebo over 12 months [<a href="#rid37">37</a>]. The trial was not designed to assess fractures, which were infrequent in both groups.</p><p></p><p class="bulletIndent1">After <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> or <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a> is discontinued, an antiresorptive agent should be administered to prevent discontinuation-associated bone loss, although the decline in BMD in men appears smaller than in women [<a href="#rid38">38</a>]. Contraindications, dosing, adverse effects, monitoring, and duration of teriparatide and abaloparatide therapy are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Denosumab</strong> – <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">Denosumab</a><strong> is a potent antiresorptive agent that </strong>may have a role for the treatment of osteoporosis in men who are intolerant of or unresponsive to other therapies and in those with impaired kidney function. Denosumab increases BMD in men with low bone mass [<a href="#rid39">39</a>], but it has not yet been shown to reduce fracture risk in men, except for men with prostate cancer receiving androgen deprivation therapy. (See  <a class="medical medical_review" href="/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Osteoporosis and bone fractures'</a>.)</p><p></p><p class="bulletIndent1">Delaying or discontinuing <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> therapy increases the risk of multiple rebound vertebral fractures, a phenomenon documented primarily in women but also reported in men [<a href="#rid40">40</a>]. This issue is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Discontinuation or delay of denosumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romosozumab</strong> – <a class="drug drug_general" data-topicid="120976" href="/d/drug information/120976.html" rel="external">Romosozumab</a> is an agent with mixed anabolic and antiresorptive properties that is being evaluated for the treatment of men with osteoporosis [<a href="#rid41">41-43</a>]. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Romosozumab'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a randomized trial of <a class="drug drug_general" data-topicid="120976" href="/d/drug information/120976.html" rel="external">romosozumab</a> or placebo in 245 men with T-score ≤-2.5 or ≤-1.5 plus a history of fragility fracture, romosozumab increased BMD at the lumbar spine and total hip more than placebo over 12 months [<a href="#rid41">41</a>]. Fractures, reported as a safety outcome, were infrequent in both groups. There were more serious cardiovascular adverse events in men receiving romosozumab (4.9 versus 2.5 percent in the placebo group), although the increase was not statistically significant.</p><p></p><p class="headingAnchor" id="H2933761274"><span class="h3">Severe osteoporosis</span><span class="headingEndMark"> — </span>Men with severe osteoporosis at very high fracture risk may benefit from initial treatment with an agent with bone anabolic properties (typically <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> due to longer-term safety data), given evidence indicating maximization of bone density gains when anabolic agents are given prior to antiresorptive treatments [<a href="#rid44">44</a>], as well as data suggesting superiority of anabolic agents over antiresorptive agents for reducing vertebral fracture risk [<a href="#rid45">45-47</a>]. <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">Abaloparatide</a> and <a class="drug drug_general" data-topicid="120976" href="/d/drug information/120976.html" rel="external">romosozumab</a> are alternative anabolic agents. Abaloparatide has received regulatory approval in the United States for the treatment of men at high risk for osteoporotic fracture. Romosozumab is approved for use in men at high risk for fracture in some countries, but not in the United States [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Selection of anabolic agent'</a>.)</p><p>Factors that may indicate a very high fracture risk and thus warrant consideration of initial treatment with an anabolic agent are the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Very low T-score (eg, T-score of ≤-3.0) even in the absence of fracture(s)</p><p class="bulletIndent1"><span class="glyph">●</span>T-score of ≤-2.5 plus a fragility fracture</p><p class="bulletIndent1"><span class="glyph">●</span>Severe or multiple vertebral fractures</p><p></p><p>After <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> or other anabolic agent is discontinued, an antiresorptive agent should be administered, although bone loss after discontinuation of anabolic therapy may be less pronounced in men than women [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Management after teriparatide'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Combination therapy</span><span class="headingEndMark"> — </span>Concurrent treatment with <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> and <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> attenuates the ability of teriparatide to increase spine and hip BMD in men [<a href="#rid48">48</a>]. Thus, we do not recommend concurrent use of bisphosphonates with teriparatide for the management of osteoporosis. However, the immediate use of bisphosphonates <strong>after</strong> teriparatide is withdrawn may maintain or even increase BMD in men further [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Management after teriparatide'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">MONITORING THE RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. For patients starting on therapy, we typically obtain a follow-up dual-energy x-ray absorptiometry (DXA) of hip and spine after one to two years and, if bone mineral density (BMD) is stable or improved, we monitor less frequently thereafter. There may be limitations to the use of spine DXA in aging men due to interference from osteophytes and vascular calcifications on the spine measurement. The use of biochemical markers of bone turnover to monitor response to therapy is not well studied in men and is not routinely recommended.</p><p>Monitoring for the identification of patients who may require a change in therapy is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p><p class="headingAnchor" id="H2749287772"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>There is currently no consensus on how long to continue bisphosphonate therapy in men. In postmenopausal women with osteoporosis, <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> have been shown to reduce fracture risk for up to 10, 7, and 6 years, respectively. Due to concerns about possible long-term risks of bisphosphonates (see  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>), many experts recommend a "drug holiday" in selected groups of women and in men. We suggest suspending bisphosphonate treatment for men who have taken alendronate for five years or who have received zoledronic acid once yearly for three years if their bone mineral density (BMD) is stable, they have not had previous fragility fractures, and they are at low risk for fracture in the near future. BMD should be monitored approximately every two years after suspending therapy, and therapy should generally be resumed if BMD declines significantly or if the patient develops a new fragility fracture.</p><p>This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Duration of therapy'</a>.)</p><p>The duration of <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> and <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a> is reviewed separately. (See  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Duration of therapy'</a> and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Management after teriparatide'</a> and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Management after abaloparatide'</a>.)</p><p class="headingAnchor" id="H2767563819"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/116407.html" rel="external">"Society guideline links: Clinical densitometry"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15536.html" rel="external">"Patient education: Calcium and vitamin D for bone health (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2169.html" rel="external">"Patient education: Calcium and vitamin D for bone health (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lifestyle measures</strong> – Important lifestyle measures include exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use for all men with osteoporosis. (See <a class="local">'Lifestyle measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ensure optimal calcium and vitamin D intake</strong> – Although the optimal intake (diet plus supplement) has not been clearly established in men with osteoporosis, approximately 1000 to 1200 mg of calcium and 600 to 800 international units of vitamin D daily are generally suggested. In men with osteoporosis (T-score below -2.5) and inadequate dietary intake, we suggest calcium and vitamin D supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent1">The dose of calcium and vitamin D may vary in individuals with coexisting medical conditions. (See  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis", section on 'Coexisting medical problems'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of underlying conditions</strong> – If osteoporosis is due to another condition (eg, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> deficiency), the underlying cause should be treated. (See <a class="local">'Management of underlying conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection for osteoporosis pharmacotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For men with osteoporosis (history of fragility fracture, or in men ≥50 years, a T-score below -2.5), we recommend osteoporosis pharmacotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For testosterone-treated hypogonadal men who have a high risk for fracture, we suggest the addition of osteoporosis pharmacotherapy to <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). High-risk groups might include hypogonadal men whose bone mineral density (BMD) T-score is ≤-2.5 after adequate testosterone replacement therapy for ≥2 years; men on high-dose glucocorticoids; men with frequent falls; men who have had a recent fragility fracture, particularly if BMD T-score is ≤-2.5 at any skeletal site; or men with T-scores ≤-3.0. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For men aged ≥50 years with T-scores between -1.0 and -2.5 who are at high risk for fracture, we suggest osteoporosis pharmacotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). A reasonable threshold for high risk that may be cost effective in some settings is a 10-year probability (using the Fracture Risk Assessment Tool [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2059" target="_blank">FRAX</a>]) of hip fracture or combined major osteoporotic fracture of ≥3.0 or ≥20 percent, respectively. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of initial therapy</strong> – For osteoporosis pharmacotherapy in most men, we suggest bisphosphonates as first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We favor <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> or <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a> over other available bisphosphonates because of clinical trial data demonstrating efficacy in men with osteoporosis. (See <a class="local">'Initial therapy: Bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent1">Men who have esophageal disorders, gastrointestinal intolerance to oral bisphosphonates, certain types of bariatric surgery (eg, Roux-en-Y gastric bypass), or an inability to follow the dosing requirements of oral bisphosphonates should not be treated with oral bisphosphonates and can be treated instead with intravenous (IV) bisphosphonate therapy. <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">Zoledronic acid</a> is the only IV bisphosphonate that has demonstrated efficacy for fracture prevention in men. (See <a class="local">'Contraindications or intolerance to oral bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">Teriparatide</a>, <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">abaloparatide</a>, and <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a> are alternatives in men who are intolerant of or unresponsive to any bisphosphonate. (See <a class="local">'Contraindications/intolerance to any bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe osteoporosis</strong> – For men who are at very high risk for fracture (eg, T-score ≤-2.5 and at least one fragility fracture, T-score of ≤-3.0 even in the absence of fractures, severe or multiple vertebral fractures), we suggest <a class="drug drug_general" data-topicid="10178" href="/d/drug information/10178.html" rel="external">teriparatide</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). More long-term safety data are available for teriparatide than for other anabolic agents. <a class="drug drug_general" data-topicid="112992" href="/d/drug information/112992.html" rel="external">Abaloparatide</a> and <a class="drug drug_general" data-topicid="120976" href="/d/drug information/120976.html" rel="external">romosozumab</a> are alternative anabolic agents. After non-bisphosphonate agents are discontinued, an antiresorptive agent should be administered to prevent discontinuation-associated bone loss. (See <a class="local">'Severe osteoporosis'</a> above and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Management after teriparatide'</a> and  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Romosozumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – While there are a number of approaches to monitoring therapy, no consensus exists on the optimal approach. Patients can be monitored with BMD measurements, as is recommended for postmenopausal women. For patients starting on therapy, we typically obtain a follow-up dual-energy x-ray absorptiometry (DXA) of hip and spine after one to two years and, if BMD is stable or improved, we monitor less frequently thereafter. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003; 32:468.</a></li><li><a class="nounderline abstract_t">Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152:380.</a></li><li><a class="nounderline abstract_t">Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878.</a></li><li><a class="nounderline abstract_t">Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162:2217.</a></li><li><a class="nounderline abstract_t">Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163:2165.</a></li><li><a class="nounderline abstract_t">Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005; 16:953.</a></li><li><a class="nounderline abstract_t">Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001; 86:4098.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106:354.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776.</a></li><li><a class="nounderline abstract_t">Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386.</a></li><li><a class="nounderline abstract_t">Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358.</a></li><li><a class="nounderline abstract_t">Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802.</a></li><li><a class="nounderline abstract_t">Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503.</a></li><li><a class="nounderline abstract_t">Basurto L, Zarate A, Gomez R, et al. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 2008; 11:140.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med 2017; 177:471.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Lee H, Leder BZ, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest 2016; 126:1114.</a></li><li><a class="nounderline abstract_t">Bhasin S, Lincoff AM, Basaria S, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J 2022; 245:41.</a></li><li><a class="nounderline abstract_t">LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33:2049.</a></li><li><a class="nounderline abstract_t">Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.</a></li><li class="breakAll">http://www.shef.ac.uk/NOGG/index.html (Accessed on March 10, 2011).</li><li><a class="nounderline abstract_t">Ensrud KE, Taylor BC, Peters KW, et al. Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study. BMJ 2014; 349:g4120.</a></li><li><a class="nounderline abstract_t">Crandall CJ, Newberry SJ, Diamant A, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 2014; 161:711.</a></li><li><a class="nounderline abstract_t">Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P. The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos 2011; 2011:259818.</a></li><li><a class="nounderline abstract_t">Nayak S, Greenspan SL. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc 2017; 65:490.</a></li><li class="breakAll">http://www.shef.ac.uk/NOGG/NOGG_Pocket_Guide_for_Healthcare_Professionals.pdf (Accessed on June 21, 2012).</li><li><a class="nounderline abstract_t">Qaseem A, Forciea MA, McLean RM, et al. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med 2017; 166:818.</a></li><li><a class="nounderline abstract_t">Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604.</a></li><li><a class="nounderline abstract_t">Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86:5252.</a></li><li><a class="nounderline abstract_t">Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004; 24:110.</a></li><li><a class="nounderline abstract_t">Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26:427.</a></li><li><a class="nounderline abstract_t">Ringe JD, Farahmand P, Faber H, Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol Int 2009; 29:311.</a></li><li><a class="nounderline abstract_t">Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24:719.</a></li><li><a class="nounderline abstract_t">Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799.</a></li><li><a class="nounderline abstract_t">Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367:1714.</a></li><li><a class="nounderline abstract_t">Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9.</a></li><li><a class="nounderline abstract_t">Czerwinski E, Cardona J, Plebanski R, et al. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. J Bone Miner Res 2022; 37:2435.</a></li><li><a class="nounderline abstract_t">Leder BZ, Neer RM, Wyland JJ, et al. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 2009; 94:2915.</a></li><li><a class="nounderline abstract_t">Orwoll E, Teglbjærg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97:3161.</a></li><li><a class="nounderline abstract_t">Anastasilakis AD, Evangelatos G, Makras P, Iliopoulos A. Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Rep 2020; 12:100267.</a></li><li><a class="nounderline abstract_t">Lewiecki EM, Blicharski T, Goemaere S, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab 2018; 103:3183.</a></li><li><a class="nounderline abstract_t">Gennari L, Bilezikian JP. New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother 2018; 19:253.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT03512262 (Accessed on May 31, 2021).</li><li><a class="nounderline abstract_t">Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. Endocr Pract 2020; 26:777.</a></li><li><a class="nounderline abstract_t">Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.</a></li><li><a class="nounderline abstract_t">Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391:230.</a></li><li><a class="nounderline abstract_t">Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 2017; 377:1417.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216.</a></li><li><a class="nounderline abstract_t">Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992.</a></li></ol></div><div id="topicVersionRevision">Topic 2059 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753862" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The components of excess mortality after hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231569" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meta-analysis: excess mortality after hip fracture among older women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10093980" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mortality after all major types of osteoporotic fracture in men and women: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390065" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Undertreatment of osteoporosis in men with hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557214" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928798" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The near absence of osteoporosis treatment in older men with fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549632" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3544993" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674186" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253305" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8954042" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22675062" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Osteoporosis in men: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764753" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821290" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372695" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of testosterone treatment on bone mineral density in men over 65 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241231" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26901812" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871580" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35478046" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The clinician's guide to prevention and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940232" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940232" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24994809" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199883" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21776371" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28304090" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28304090" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492856" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979796" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alendronate for the treatment of osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701687" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13680141" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16001181" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762944" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19049326" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878149" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Zoledronic acid and clinical fractures and mortality after hip fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23113482" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fracture risk and zoledronic acid therapy in men with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12510800" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36190391" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19435827" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723310" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32373677" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29931216" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29350069" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New and developing pharmacotherapy for osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29350069" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : New and developing pharmacotherapy for osteoporosis in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33471647" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003959" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Teriparatide or alendronate in glucocorticoid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29129436" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28892457" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500805" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15175844" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)].</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
